Selecxine has raised a total of $55M in funding over 2 rounds 

including angel investment round.

Selecxine develops and discovers therapeutic antibodies for cancer treatment based on in house novel antibody 

development platform.​

Selecxine has successfully achieved $30 million in Series B investment from the major venture capital firms, 

such as Stonebridge Ventures.​

Founded in 2018, Selecxine has excelled in developing the antibody based immunotherapeutic, SCL-3010. 

Selecxine has announced that this investment will further accelerate its development process towards the clinical level.​

​

This series B round was led by the Stonebridge Ventures with the original participants including the STIC Ventures, 

Medytox Venture, Hanwha Investment & Securities, and SJ Investment Partners. Several firms also newly joined including 

the Medici Investment, UTC Investment, KCLAVIS Investment, Hyundai Venture Investment, and Hi Investment Partners.​

​

Selecxine has raised a total of $55M in funding over 2 rounds including angel investment round. 

It is interpretable that Selecxine has gained large attraction from the market with its in-house technology of developing therapeutic antibodies.

​

Article source link: https://www.yakup.com/news/index.html?mode=view&cat=12&nid=267697​